文献速递心境障碍

利用安慰剂效应与减轻反安慰剂效应:精神科与医学临床实践的意义

Harnessing placebo effects and mitigating nocebo effects: implications for clinical practice in psychiatry and medicine.
PubMed 文献 · Lancet Psychiatry · 2026-01-01

本文是两篇关于重新概念化安慰剂与反安慰剂效应综述中的第一篇,讨论在临床实践中利用安慰剂效应和减轻反安慰剂效应的理由、策略与伦理考量。文章指出精神科试验中安慰剂组缓解率可接近50%,并探讨目标患者群体、纯与不纯安慰剂、授权欺骗、诚实开放标签安慰剂、通过条件化安慰剂减少药物剂量、反安慰剂教育及重构等应用方式。

要点

  • 精神科新型治疗设备试验中安慰剂组缓解率接近50%,应探讨如何利用而非仅视为试验失败。
  • 反安慰剂效应机制有新见解,需减轻负面期望对症状和药物副作用的影响。
  • 临床可考虑目标患者群体、纯与不纯安慰剂、授权欺骗、开放标签安慰剂及条件化安慰剂减药等策略。

核心结论

  • 应重新概念化安慰剂效应,从试验中的干扰因素转变为可在临床实践中利用的治疗资源,同时减轻反安慰剂效应。

研究设计与样本

  • 本文为综述(两篇中的第一篇),讨论利用安慰剂效应和减轻反安慰剂效应的理由、策略与伦理考量。

主要发现

  • 精神科新型治疗设备试验中安慰剂组缓解率接近50%。
  • 对反安慰剂效应机制已有重要新见解,涉及负面期望对症状和药物副作用的影响。

关键数值与推荐

  • 文中讨论的策略包括目标患者群体、传统纯与不纯安慰剂、授权欺骗、诚实开放标签安慰剂、通过条件化安慰剂减少药物剂量、反安慰剂教育、反安慰剂重构、转变心态和增强治疗情境。

临床怎么用

  • 临床可考虑利用开放标签安慰剂、条件化安慰剂减药、反安慰剂教育和重构等方式,并关注治疗情境与心态转变。

局限性

  • 本文为综述,未报告原始研究样本量、置信区间或P值等定量数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In psychiatry and medicine, there is a long history of framing placebo effects primarily as nuisance factors and focusing on how they should be minimised in clinical trials. However, a new view on placebo effects has emerged with advances in understanding their complex neurobiology and observations of unexpectedly large placebo responses in recent psychiatric trials. In particular, novel therapeutic device trials for depression have shown placebo-group remission rates nearing 50%. Instead of considering these studies as a failure and moving on, questions should be raised on how such responses are possible and how these effects can be harnessed for the benefit of patients. There have also been important new insights into the mechanisms of nocebo effects and analogous questions on how best to mitigate the effect of negative expectations on symptoms and medication side-effects. In this Review, paper 1 of 2 on reconceptualising placebo and nocebo effects, we discuss the rationale, strategies, and ethical considerations related to harnessing placebo effects and mitigating nocebo effects in clinical practice, including discussion of target patient populations, traditional pure and impure placebos, authorised deception, honest open-label placebo, pharmacotherapy dose reduction via conditioned placebo, nocebo education, nocebo reframing, and other ways to apply principles underlying placebo and nocebo effects, such as shifting mindsets and enhancing the therapeutic context. Lastly, we highlight the centrality of this topic to psychiatry, but explore how better understanding the interactions of mind, brain, and body-epitomised by placebo and nocebo effects-has crucial relevance across medicine.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Burke MJ, Sandra DA, Peciña M, et al. Harnessing placebo effects and mitigating nocebo effects: implications for clinical practice in psychiatry and medicine. Lancet Psychiatry. 2026. PMID: 41997696. doi:10.1016/S2215-0366(25)00340-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。